CTIS2023-506258-19-00招募中1 期
Patient reported outcomes in term of swallowing and quality of life after prophylactic versus reactive percutaneous endoscopic gastrostomy tube placement in advanced head and neck cancer patients treated with definitive chemo-radiotherapy - IJB-RT-HNC-001
Institut Jules Bordet0 个研究点目标入组 121 人开始时间: 2023年6月12日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 121
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Age = 18 years old, Women of childbearing potential must agree to use of one highly effective method of contraception prior study entry, during the course of the study and at least 6 months after the last administration of cisplatin., Men with childbearing potential partner must agree to use condom during the course of this study and for at least 6 months after the last administration of the cisplatin, Adequate bone marrow function as defined below: - Absolute neutrophil count (ANC) =1500/µL or 1.5x109 /L - Hemoglobin = 9 g/dL - Platelets =100000/µL or 100x109 /L, Adequate liver function as defined below: - Serum total bilirubin = 1.5 x ULN. In case of known Gilbert’s syndrome < 3 x UNL is allowed - AST (SGOT)/ALT (SGPT) = 2.5 x ULN - Alkaline phosphatase = 2.5 x ULN, Adequate renal function as defined below: - Creatinine = 1.5 x UNL and creatinine clearance > 60 mL/min, Peripheral neuropathy = grade 1, Hear impaired = grade 1, Completion of all necessary screening procedures within 15 days prior to randomisation., Signed Informed Consent form (ICF) obtained prior to any study related procedure., Ability to understand and complete the questionnaires (language proficiency, cognitive functioning) as judged by the principal investigator upon screening), ECOG performance status = 2, Female and Male, Newly diagnosed, histologically confirmed primary squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, larynx and nasopharyngeal carcinoma, Candidate for curative intent radiotherapy and systemic treatment, No prior or current anticancer treatment for the HNC(e.g. neo-adjuvant chemotherapy, surgery), Diagnosis biopsy results available at the time of screening, HPV/p 16 testing results available at the time of screening for oropharyngeal carcinoma, Serum pregnancy test (for subjects of childbearing potential) negative within 7 days prior to the 1st CCRT administration.
排除标准
- •Severe malnutrition according to the Global Leadership Initiative on Malnutrition (GLIM) criteria, Dysphagia requiring a liquid or puree texture modified diet (grade = 2 (CTCAE_v.5), Distant metastasis, Serious coagulation disorders (INR>1.5, PTT> 50s, platelets <50000/mm3), Subject with a significant medical, neuro-psychiatric, or surgical condition, currently uncontrolled by treatment, which, in the principal investigator’s opinion, may interfere with completion of the study., Other malignancies in the 3 years prior to study entry except of surgically cured carcinoma in situ of the cervix, in situ breast cancer, incidental finding of stage T1a or T1b prostate cancer, and basal/squamous cell carcinoma of the skin, Pregnant and/or lactating women., Known hypersensitivity to the study drug (cisplatin) or excipients.
研究者
相似试验
尚未招募
不适用
Clinical study of an effectiveness of swallowing dynamics evaluation on swallowing sound for dysphagia patientsDysphagiaJPRN-UMIN000034943Tokushima university50
尚未招募
不适用
Examination of the effectivenes of swallowing training using the ballon type manometoryJPRN-UMIN000013139International University of Health and Welfare20
招募中
不适用
Evaluation of the usefulness of a swallowing electrical stimulator in maintaining swallowing function in patients after extubation: a randomized controlled trialpost-extubation dysphagia(PED)JPRN-UMIN000046443Hitachi general hospital40
尚未招募
Unknown
Patient reported outcomes of acute swallowing problems in patients of non small cell lung cancer treated with radical radiotherapy with or without chemotherapyCTRI/2023/08/056401ot applicable
已完成
不适用
Swallowing problems - empirical evaluation of the swallowability of solid oral drugs (part 4)R13.9DRKS00004174niversitätsklinikum Heidelberg151